Advancing understanding on Mpox Clade 2: Consortium Members presented findings at the 2023 CROI Conference

In a significant stride towards understanding the transmission patterns and clinical outcomes of Mpox clade 2, our team unveiled first research results at the prestigious CROI conference in Seattle, held in February 2023.

With over 80,000 reported cases of clade 2b Mpox outside of its traditionally endemic African countries in 2022, the urgency to comprehensively characterize this variant’s clinical profile has never been greater. Unlike its clade 1 counterpart, clade 2b Mpox exhibits distinct transmission patterns and clinical features, necessitating a systematic approach to its clinical characterization.

Presenting our findings in the form of a poster, our team shed light on the unique characteristics of clade 2b Mpox, providing insights into its transmission dynamics and associated clinical outcomes. Our ultimate aim is to advance informed strategies for the prevention and management of this strain by healthcare practitioners.